Enzyre, a Nijmegen, Netherlands-based provider of ambulant diagnostic technology for blood coagulation testing, raised €12M in Series A funding.
The round was led by Oost NL, with participation from i&i Biotech Fund, Demcon Investment, Takeda Ventures and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government.
The company intends to use the funds to accelerate development of proprietary ambulant diagnostic platform and establish manufacturing capabilities.
Led by CEO Guido Maertens, Enzyre provides a platform that requires a small volume of blood to measure up to sixteen reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure, at home, on the road or in a critical care setting. This offers benefits to patients: avoid crisis situations driven by changes in coagulation status, empower patients to optimize treatment themselves, reduce GP consultation visits and, as a personalized diagnostic tool, offer support in a telemedicine setting.
Enzyre’s first product, Hemophilia EnzyCard, uses the company’s proprietary EnzyPad platform technology to determine the coagulation status of patients with hemophilia, a rare genetic disorder that is estimated to affect over 800,000 people worldwide.
FinSMEs
02/11/2022